Breast Cancer

Latest News


Women with hormone-negative breast cancers may not be able to benefit from tamoxifen and aromatase inhibitors, but a subset of patients with HER2-positive breast cancer are able to take advantage of advances such as Herceptin and Tykerb. For women with hormone- and HER2-negative cancers, or triple negative, new research into what drives these cancers and prevent recurrence may increase treatment options and benefit this population.

Finding Your Compass

New research and tools illuminate the multiple treatment paths faced by patients with early-stage invasive breast cancer.